GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Palatin Technologies Inc (FRA:PTN) » Definitions » Debt-to-Asset

Palatin Technologies (FRA:PTN) Debt-to-Asset : 0.14 (As of Sep. 2024)


View and export this data going back to 1993. Start your Free Trial

What is Palatin Technologies Debt-to-Asset?

Palatin Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €0.31 Mil. Palatin Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €0.12 Mil. Palatin Technologies's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was €3.08 Mil. Palatin Technologies's debt to asset for the quarter that ended in Sep. 2024 was 0.14.


Palatin Technologies Debt-to-Asset Historical Data

The historical data trend for Palatin Technologies's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Palatin Technologies Debt-to-Asset Chart

Palatin Technologies Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.02 0.03 0.06 0.06

Palatin Technologies Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.06 0.06 0.06 0.14

Competitive Comparison of Palatin Technologies's Debt-to-Asset

For the Biotechnology subindustry, Palatin Technologies's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Palatin Technologies's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Palatin Technologies's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Palatin Technologies's Debt-to-Asset falls into.



Palatin Technologies Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Palatin Technologies's Debt-to-Asset for the fiscal year that ended in Jun. 2024 is calculated as

Palatin Technologies's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Palatin Technologies  (FRA:PTN) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Palatin Technologies Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Palatin Technologies's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Palatin Technologies Business Description

Traded in Other Exchanges
Address
4B Cedar Brook Drive, Cranbury, NJ, USA, 08512
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.